Thorazine

(Chlorpromazine)

ApprovedSmall molecule

GGlaxo Dba Glaxosmithkline

Thorazine is one of 82 small molecule programs targeting Delirium. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

DeliriumRecruiting

SchizophreniaActive, not recruiting

DeliriumPhase 3

Recruiting

SchizophreniaApproved

Active, not recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Thorazine

GGlaxo Dba Glaxosmithkline

Approved

2 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Delirium

NCT05431595

Q2 2027

PreclinicalActive, not recruiting

Advanced Malignant Neoplasm

NCT03021486

Clinical

Trials by Indication[1]

COVID-192 trials

Repurposing of Chlorpromazine in Covid-19 Treatment

Withdrawn·—·Phase 3·NCT04366739

Administration of Chlorpromazine as a Treatment for COVID-19

Unknown status·—·Phase 2/3·NCT04354805·100 enrolled

Schizophrenia2 trials

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02600741·296 enrolled

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

Terminated·HHarvard Medical School (HMS and HSDM)·Phase 4·NCT00169039·66 enrolled

Stage III Colon Cancer1 trial

Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Withdrawn·SSadat City University·Phase 1/2·NCT05433402

Delirium1 trial

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Recruiting·MM.D. Anderson Cancer Center·Phase 2/3·NCT05431595·42 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00882518·388 enrolled

6 more indications

Age1 trial

The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.

Unknown status·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT03183310·14 enrolled

Withdrawal1 trial

How to Treat Opiate Withdrawal in Neonates

Completed·UUniversity of Zurich·Phase 3·NCT02810782·120 enrolled

Pain1 trial

Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

Completed·—·N/A·NCT01404364·36 enrolled

Olanzapine1 trial

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Completed·MMelbourne Health·Phase 4·NCT00202293·83 enrolled

Glioblastoma1 trial

Chlorpromazine and Standard of Care in Glioblastoma

Completed·MMohammed Milhem·Phase 1·NCT05190315·10 enrolled

Advanced Malignant Neoplasm1 trial

Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT03021486·70 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

THORAZINE

NDA NDA011120

Jan 1, 1982

THORAZINE

NDA NDA009149

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Chlorpromazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chlorpromazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chlorpromazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011120). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Thorazine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

COVID-192 trials

Schizophrenia2 trials

Stage III Colon Cancer1 trial

Delirium1 trial

Efficacy and Safety1 trial

Age1 trial

Withdrawal1 trial

Pain1 trial

Olanzapine1 trial

Glioblastoma1 trial

Advanced Malignant Neoplasm1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News